![]() ![]() And so for that subset of patients, this would be my standard frontline option. Importantly, the benefit was only seen in patients with CPS, or combined positive score, greater than or equal to 10. Part 1 was open-label and looked at the safety and tolerability of Keytruda with either nab-paclitaxel, paclitaxel or gemcitabine/carboplatin in 30 patients. KEYNOTE-355 is a randomized, two-part, placebo-controlled Phase 3 trial (, NCT02819518) evaluating KEYTRUDA in combination with one of three different chemotherapies compared with placebo plus one of the three chemotherapy regimens for the treatment of locally recurrent inoperable or metastatic TNBC that has not been previousl. I'm excited to be able to offer this to my patients in the frontline setting. KEYNOTE-355 is a randomized, two-part Phase III trial. So immunotherapy has really been a game changer in oncology altogether, but breast cancer has sort of fallen behind in terms of the benefits seen in other tumor types. So at a median follow-up of 44 months, the overall survival was 23 months for the combination of pembrolizumab with chemotherapy versus 16 months for chemotherapy alone, which is I think, a meaningful clinical benefit. Scopri le caratteristiche, le funzioni e tutto ciò che Keynote può fare su Mac, iPad o iPhone. Previously we had known that adding pembrolizumab to a variety of chemotherapy agents improved progression-free survival, but what these updated data show us is there's an improvement in overall survival, which is something that's really rarely seen in clinical trials for metastatic triple-negative breast cancer. Another really exciting clinical trial coming out of the ESMO meeting this year is a study looking at the addition of immunotherapy to standard chemotherapy for frontline treatment of triple-negative breast cancer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |